Quantification of TDP-43 levels in CSF from patients with ALS, FTLD, and various other neurological disorders was achieved using different biochemical techniques resulting in contradictory recommendations on whether TDP-43 may serve as a biomarker for the diagnosis of ALS and differentiating it from other neurological diseases. This evidence concerns the gene TARDBP and amyotrophic lateral sclerosis.